For the year ending 2025-12-31, FBIO had $21,786K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -32,915 |
| Depreciation expense | 403 |
| Loss on disposal of property and equipment | 0 |
| Bad debt (recovery) expense | -211 |
| Amortization of debt discount | 1,404 |
| Accretion of partner company convertible preferred shares | 0 |
| Gain on termination of partner company lease | 394 |
| Loss on extinguishment of debt | 0 |
| Amortization of acquired intangible assets | 4,258 |
| Settlement of partner company payables | -2,104 |
| Reduction in the carrying amount of operating lease right-of-use assets | 1,943 |
| Stock-based compensation expense | 28,739 |
| Change in fair value of investment | 15,075 |
| Common shares issued for dividend on partner company's convertible preferred shares | 0 |
| Change in fair value of partner companies' warrant liabilities | 398 |
| Research and development - licenses acquired, expense | 0 |
| Gain from deconsolidation of subsidiary | 27,127 |
| Asset impairment loss | 0 |
| Accounts receivable | 19,341 |
| Inventory | -4,807 |
| Other receivables - related party | -13 |
| Prepaid expenses and other current assets | -1,546 |
| Other assets | -330 |
| Accounts payable and accrued expenses | -7,971 |
| Income taxes payable | -576 |
| Lease liabilities | -2,226 |
| Other liabilities | -1,678 |
| Net cash used in operating activities | -65,777 |
| Acquired intangible assets | 0 |
| Proceeds from sale of property and equipment | 1,165 |
| Net cash increase upon deconsolidation of subsidiary | 8,956 |
| Net cash provided by (used in) investing activities | 10,121 |
| Payment of series a perpetual preferred stock dividends | 0 |
| Proceeds from issuance of common stock for public offering, net | 0 |
| Proceeds from issuance of common stock for at-the-market offering, net | 1,008 |
| Proceeds from issuance of common stock under espp | 87 |
| Exercise of warrants for cash | 2,647 |
| Proceeds from partner companies' espp | 217 |
| Partner company's dividends declared and paid | 664 |
| Partner company's redemption of preferred shares | 265 |
| Proceeds from partner companies' equity offerings and warrant exercises, net | 61,621 |
| Proceeds from partner companies' at-the-market offering, net | 19,052 |
| Proceeds from exercise of partner company's options, net | 0 |
| Repayment of oaktree note and debt issuance costs | 5,561 |
| Repayment of partner company installment payments - licenses | 625 |
| Stock and warrants issued for exchange of partner company preferred shares | 0 |
| Proceeds from long-term debt, net | -75 |
| Proceeds from partner company's long-term debt, net | 0 |
| Net cash provided by financing activities | 77,442 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 21,786 |
| Cash and cash equivalents and restricted cash at beginning of period | 58,815 |
| Cash and cash equivalents and restricted cash at end of period | 80,601 |
Fortress Biotech, Inc. (FBIO)
Fortress Biotech, Inc. (FBIO)